These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan. Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889 [TBL] [Abstract][Full Text] [Related]
27. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046 [TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Shenoi S; Wallace CA Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916 [TBL] [Abstract][Full Text] [Related]
29. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. Katsicas MM; Russo RA Clin Rheumatol; 2009 Aug; 28(8):985-8. PubMed ID: 19322622 [TBL] [Abstract][Full Text] [Related]
30. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]. de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652 [TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Prince FH; Twilt M; ten Cate R; van Rossum MA; Armbrust W; Hoppenreijs EP; van Santen-Hoeufft M; Koopman-Keemink Y; Wulffraat NM; van Suijlekom-Smit LW Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. Bracaglia C; Buonuomo PS; Tozzi AE; Pardeo M; Nicolai R; Campana A; Insalaco A; Cortis E; DE Benedetti F J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254 [TBL] [Abstract][Full Text] [Related]
33. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review. Woolacott NF; Khadjesari ZC; Bruce IN; Riemsma RP Clin Exp Rheumatol; 2006; 24(5):587-93. PubMed ID: 17181932 [TBL] [Abstract][Full Text] [Related]
34. Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab. Matsuno H Mod Rheumatol; 2010 Dec; 20(6):561-5. PubMed ID: 20552246 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age. Giménez-Roca C; Iglesias E; Torrente-Segarra V; Bou R; Sánchez-Manubens J; Calzada-Hernández J; Hernández S; Ricart S; Antón J Rheumatol Int; 2015 Feb; 35(2):323-6. PubMed ID: 25086629 [TBL] [Abstract][Full Text] [Related]
36. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G; Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489 [TBL] [Abstract][Full Text] [Related]
37. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective? Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101 [TBL] [Abstract][Full Text] [Related]
38. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924 [TBL] [Abstract][Full Text] [Related]
39. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Haapasaari J; Kautiainen H; Hannula S; Pohjankoski H; Hakala M Clin Exp Rheumatol; 2002; 20(6):867-70. PubMed ID: 12508784 [TBL] [Abstract][Full Text] [Related]